Intuity Medical, Inc. (POGO)
Intuity Medical is a commercial-stage medical technology and digital health company focused on developing comprehensive solutions to improve the health and quality of life of people with diabetes.
We developed our first commercial product, the POGO Automatic Blood Glucose Monitoring System, or POGO Automatic, to revolutionize the blood glucose testing process for individuals living with diabetes.
POGO Automatic is an FDA cleared, automated, self-contained handheld monitor that enables patients to accurately measure blood glucose levels within seconds.
POGO Automatic offers full connectivity through our secure cloud-based digital health ecosystem, the Patterns app, which centralizes each patient’s blood glucose testing data in a digital form that can be shared with healthcare providers and others who play a central role in assisting with a patient’s diabetes treatment and testing regimen.
We believe the convenience and simplicity of POGO Automatic will help remove the barriers to traditional glucose testing for people diagnosed with diabetes, and help them achieve their glucose level goals.
3500 West Warren Avenue
Fremont, CA 94538
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Emory Anderson||President, Chief Executive Officer and Director|
|Timothy Buskey||Chief Market Access Officer and Senior Vice President of Market Access and Channel Management|
|Tammy Cameron||Chief Financial Officer and Senior Vice President of Finance and Human Resources|
|Robb Hesley||Chief Operating Officer and Senior Vice President of Product Development, Manufacturing, Quality and Information Technology|
|Dean Zikria||Chief Commercial Officer and Senior Vice President of Sales and Marketing|
|Rebecca Robertson||Chairperson and Director|
|Michael Bornitz, CFA, CPA||Director|
Latest SEC Filings
|Jun 3, 2022||RW||Registration Withdrawal Request|
|Sep 17, 2021||S-1||General form for registration of securities under the Securities Act of 1933|
|Aug 31, 2021||DRS/A||Draft Registration Statement|
|Jul 26, 2021||DRS/A||Draft Registration Statement|
|Jun 4, 2021||DRS||Draft Registration Statement|
|May 29, 2019||D||Notice of Exempt Offering of Securities|
|Feb 15, 2018||D/A||Notice of Exempt Offering of Securities|
|Jan 10, 2018||D||Notice of Exempt Offering of Securities|
|Jan 9, 2017||D/A||Notice of Exempt Offering of Securities|
|Nov 9, 2016||D||Notice of Exempt Offering of Securities|